JUNS · Jupiter Neurosciences, Inc.
$3.27
-0.16 (-4.66%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.64M
Shares
770,081
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Christer Rosén | Chairman of the Board and Chief Executive Officer | $154,076 |
| Saleem Elmasri | Chief Financial Officer | $127,006 |
| Marshall Hayward | Chief Scientific Officer | $107,800 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christer Rosén | Chairman of the Board and Chief Executive Officer | $1,437,367 |
| Marshall Hayward | Chief Scientific Officer | $1,141,710 |
| Saleem Elmasri | Chief Financial Officer | $778,503 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Tomas J. Philipson, Ph.D. | member of the Board | Appointed | 2026-06-30 |
| Allison W. Brady | member of the Audit Committee | Resigned | 2026-06-22 |
| Allison W. Brady | member of the Board of Directors | Resigned | 2026-06-22 |
| Alison Silva | Chief Operating Officer and President | Appointed | 2026-06-05 |